代谢功能障碍相关的脂肪性肝病治疗及热门靶点的药物研究进展  

Research progress in the current treatment and drugs to popular targets for metabolic dysfunction-associated steatotic liver disease

作　　者：熊晗晖 姜金生 蔡霈[3] 谢惠平 李跃忠 盛敏 李刚 李国军 邓家国 Xiong Hanhui;Jiang Jinsheng;Cai Pei;Xie Huiping;Li Yuezhong;Sheng Min;Li Gang;Li Guojun;Deng Jiaguo(Changde Yungang Biotechnology Co.,Ltd,Changde 415001,China;Xiangya Hospital of Central South University,Changsha 410008,China;Hunan Provincial Maternal and Child Health Care Hospital,Changsha 410008,China)

机构地区：[1]常德云港生物科技股份有限公司,湖南常德415001 [2]中南大学湘雅医院,湖南长沙410008 [3]湖南省妇幼保健院,湖南长沙410008

出　　处：《实用药物与临床》2024年第5期374-379,共6页Practical Pharmacy and Clinical Remedies

基　　金：湖南省药科联合基金项目(2022JJ80097);常德市科技重大项目(常财企指(2021)36号)。

摘　　要：代谢功能障碍相关的脂肪性肝病发病率高、发病机制复杂性,与肥胖、代谢紊乱和心血管等疾病息息相关。随着生活水平的提高,这类疾病的患病率在我国呈逐年上升趋势,甚至超过全球平均值。治疗此类疾病的药物研发一直是各大药企和科研机构关注的热点。本文概述了现有的此类疾病的治疗方法,以及最热门靶点药物的最新研究进展。Metabolic dysfunction-associated steatotic liver disease(MASLD)related diseases have the characteristics of high incidence rate and complex pathogenesis,which are closely related to obesity,metabolic disorders and cardiovascular diseases.With the improvement of living standards,the incidence of MASLD in China has been increasing year by year,even exceeding the global average.The research and development of such drugs has always been a hot topic of concern for major pharmaceutical companies and research institutions.The article reviewed the available treatment methods,as well as the latest advances on drugs to the most popular target of MASLD.

关 键 词：代谢功能障碍相关的脂肪性肝病 非酒精性脂肪肝病 甲状腺激素受体激动剂β亚型 

分 类 号：R575.5[医药卫生—消化系统]